Between 2006 and 2016, the number of drug patents granted in the United States
doubled -- but not because there was an explosion in invention or innovation.
Drug companies have learned how to game the system, accumulating patents not
for new medicines but for small changes to existing ones, which allows them to
build monopolies, block competition and drive prices up. Health justice lawyer
Priti Krishtel sheds light on how we've lost sight of the patent system's
original intent -- and offers five reforms for a redesign that would serve the
public and save lives.
Read more
Between 2006 and 2016, the number of drug patents granted in the United States
doubled -- but not because there was an explosion in invention or innovation.
Drug companies have learned how to game the system, accumulating patents not
for new medicines but for small changes to existing ones, which allows them to
build monopolies, block competition and drive prices up. Health justice lawyer
Priti Krishtel sheds light on how we've lost sight of the patent system's
original intent -- and offers five reforms for a redesign that would serve the
public and save lives.
Read less